Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer (Q24795149)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Bernardo Rapoport

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Thomas Kuehr

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Paul Ruff

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Stephen Falk

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Francis Daniel

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Conrad Jacobs

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Neville Davidson

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Josef Thaler

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Blandine Boussard

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

James Carmichael

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

0 references

publication date

16 July 2004

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1

0 references

36

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1186/1471-2407-4-36

22 April 2017

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Irinotecan in the treatment of colorectal cancer: clinical overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Topoisomerase I inhibitors: topotecan and irenotecan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 September 2017

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

30 May 2018

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-4-36

21 January 2018

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-4-36

21 January 2018

A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-4-36

21 January 2018

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-4-36

21 January 2018

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-4-36

21 January 2018

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=493270

28 November 2018

Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15257756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/15257756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/15257756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15257756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15257756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/15257756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15257756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15257756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15257756

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-4-36

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15257756%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24795149&oldid=2176880517"